Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/
The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions.
With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for both clinical and commercial supply. The site will bring solid European infrastructure, a highly skilled workforce, and a strong regulatory track record to Microsize’s growing platform.
“The acquisition agreement represents a critical step in building Microsize into a global leader in particle engineering,” said TJ Higley, CEO of Microsize. “Mic Mac complements our U.S. operations perfectly, technically, operationally, and culturally. It gives our customers seamless access to high-quality services on both sides of the Atlantic, and expands our ability to support them from early development through commercial scale.”
Jan Vertommen, Vice President, Commercial Development, Lonza Advanced Synthesis, added: “Following Microsize’s acquisition of the Quakertown site in 2022, the acquisition of the Monteggio site will enable Microsize to provide customers specialized micronization services in both the US and Europe. In view of the prior engagements between the companies involved in the transaction we anticipate a smooth transition for the Mic Mac customers.”
Microsize and Schedio will jointly invest in Mic Mac to further enhance its capabilities and accelerate modernization. The partnership aims to establish an integrated European-American network for advanced particle engineering, combining Microsize’s CDMO expertise with Schedio’s process equipment and containment technologies.
“Mic Mac is an excellent fit with our belief in the ‘Power of Together,’” said Mattia Wiedemeier, CCO of Schedio Group. “Together with Microsize, we will deliver not just capacity, but innovation and agility to customers who rely on us for safety, quality, and speed. This agreement to acquire Mic Mac supports our mission to lead the next generation of integrated particle engineering solutions.”
Derek Hennecke, Chairman of Microsize, added: “With Mic Mac, Microsize will become the most focused global platform for particle size control, spanning two continents and decades of operational excellence. This is a deliberate strategy to build scale and specialization in a market that rewards technical depth, customer trust, and execution.”
The transaction is expected to close during the first quarter of 2026 subject to customary closing conditions.
About Microsize
Microsize is a contract development and manufacturing organization (CDMO) focused exclusively on particle size reduction and control technologies. Founded in 2022 through the acquisition of Lonza’s Quakertown site, Microsize is backed by experienced CDMO executives and investors. The company provides GMP-compliant milling and micronization services to pharmaceutical innovators at all stages of development. Visit www.microsize.com.
About Schedio Group
Schedio Group is a Swiss-based group of companies specializing in isolators, spray drying, micronization equipment, and services. Operating under the philosophy of “The Power of Together,” Schedio delivers fully integrated particle engineering solutions across its business units. Learn more at www.schedio.ch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251124545344/en/
Contacts
Media Contact:
TJ Higley
info@microsize.com / 215-536-5605
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera to Debut S1 E at PMRExpo 202524.11.2025 15:17:00 EET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 15:00:00 EET | Press release
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved, cladribine capsules, currently being studied in the global Phase 3 MyClad trial, could become the first oral treatment for gMG, a rare autoimmune neuromuscular disorder that causes severe muscle weakness and significantly impacts patients’ lives. The FDA’s Fast Track program is designed to facilitate the development and accelerate the review of therapies for serious conditions with unmet medical needs,
BENEFIT and Ant International Partner to Launch Alipay+ in Bahrain to Achieve Global E-Wallet Connectivity24.11.2025 14:04:00 EET | Press release
BENEFIT, the Bahraini innovator and a leading company in fintech and electronic financial transactions service, and Ant International, a leading global digital payment, digitisation and financial technology provider, headquartered in Singapore, have partnered to launch cross-border QR payments between Bahrain’s BENEFIT QR payment scheme and Ant International’s global wallet gateway, Alipay+, during 2026 to support the transition toward a more inclusive digital payments ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124405672/en/ (L-R): Hessa Husain, Deputy Chief Executive - Bahrain Credit Reference Bureau & Data Services at BENEFIT; Abdulwahed AlJanahi, Chief Executive of BENEFIT; Pietro Candela, General Manager of EMEA at Alipay+; and Yousif Al Nefaie, Deputy Chief Executive - Business Development & Services at BENEFIT. By signing a Memorandum of Understanding (MoU), both parties will explore and develop innov
NIQ Joins TikTok Marketing Partners Program Earning Media Mix Modeling Badge24.11.2025 13:00:00 EET | Press release
NIQ, a global leader in consumer intelligence, has earned a partner badge in TikTok’s newly launched Media Mix Modeling (MMM) program – a focus area within TikTok’s Marketing Partners Program. The Marketing Partners Program is composed of carefully selected third-party partners across different categories and specialties who have met TikTok’s rigorous standards for quality and expertise. Badging signals advanced proficiency in media analytics, ensuring state-of-the-art MMM measurement for marketers around the world. As a badged MMM Marketing Partner, NIQ can help advertisers measure the full funnel impact of their marketing campaigns on TikTok and TikTok Shop, enabling them to optimize strategies based on data-driven insights that look beyond last click attribution. As part of the Marketing Partners Program, TikTok’s new reporting API is integrated into NIQ, providing automated TikTok data delivery to NIQ that eliminates error-prone manual processes, accelerates NIQ’s reporting capabil
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 11:00:00 EET | Press release
LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organizations demonstrate what it looks like when ethics is not a mandate but a mindset,” said Danny Collins, SVP EMEA at LRN. “
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom